ANN ARBOR, Mich. August 13, 2008 -A new study has shown that a nasal hepatitis B vaccine elicits a dramatic immune response in animals without requiring three vaccinations, sterile syringes or refrigeration-three factors that impede the delivery of current hepatitis B vaccines.
In the study, a single dose of the nasal vaccine triggered a protective response in animals roughly 450 times greater than that elicited by currently approved human vaccines. The animal studies demonstrate a magnitude
Continue reading: Nasal Hepatitis B Vaccine Elicits Robust Immunity with a Single Dose
NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
Ann Arbor, Mich., March 17, 2008 – NanoBio Corporation reported top-level findings today from its phase 2b study of NB-001, a topical lotion to treat herpes labialis (cold sores). The randomized, double-blind, vehicle-controlled study met its primary and secondary endpoints by demonstrating clear efficacy and safety in 482 patients.
NanoBio’s uniquely formulated lotion resulted in faster healing of cold sores, at a rate never seen before by
Continue reading: NanoBio Successfully Completes Phase 2b Study in Herpes Labialis
Ann Arbor, Mich., March 6, 2008-NanoBio
Loading ...